×

CellRapeutics™ Serum from Myelofibrosis Donor (XS-0426-XU138)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This serum is derived from donors with primary or secondary myelofibrosis, characterized by progressive bone marrow scarring. It exhibits a profile of pro-fibrotic cytokines and markers of extramedullary hematopoiesis, providing a robust matrix for studying the drivers of systemic inflammation and splenomegaly.

Specific Inquiry

  • Size:
  Add to Cart

Donor Information

  • Product Name
  • CellRapeutics™ Serum from Myelofibrosis Donor
  • Cat. No.
  • XS-0426-XU138
  • Donor Age
  • Senior
  • Donor Health
  • Clinically diagnosed with primary or secondary Myelofibrosis. Serum is characterized by profound pro-inflammatory and pro-fibrotic cytokine profiles reflecting bone marrow scarring and extramedullary hematopoiesis.
  • Ethnicity
  • Diverse backgrounds available.
  • Anticoagulant
  • None (separated via centrifugation following natural coagulation).
  • Additional Donor Information
  • Each lot features serum from donors with Primary or Secondary Myelofibrosis. Profiles include JAK2/CALR/MPL mutation status, fibrosis grade, and history of JAK inhibitor therapy.
  • Clinical Profile
  • Primary or post-PV/ET status, DIPSS risk score, JAK2/CALR/MPL mutation profile, and splenomegaly assessment.

Additional Information

  • Medication History
  • Available upon request. Records of JAK inhibitors, hydroxyurea, and medications for anemia or splenomegaly management.
  • Formulation
  • Frozen
  • Cell Viability
  • Cell-free (no residual erythrocytes or leukocytes).
  • Mycoplasma Testing
  • Negative
  • Sterility Testing
  • Negative
  • Application
  • Drug Discovery, Immuno-oncology Research
  • Research Use Only
  • RUO
  • Quality Control
  • Each serum batch undergoes rigorous IRB-compliant screening, ensuring pathogen-free safety, consistent physicochemical properties, and standardized clinical characterization of disease-specific biomarkers to provide a reliable, high-purity biological matrix.
  • Storage
  • Store at -80°C or below for long-term stability, or at -20°C for up to 6 months, avoid repeated freeze-thaw cycles to preserve product quality.
  • Shiping
  • Dry Ice
  • Handling Notes
  • Thaw slowly on ice or at 4°C and centrifuge to remove cryoprecipitates, immediate aliquoting upon first thaw is recommended to maintain autoantibody functional integrity.
  • Warnings
  • Treat as potentially biohazardous human-derived material and handle strictly under BSL-2 guidelines using appropriate personal protective equipment.
  • Size
  • 1ML
  • Keywords
  • CellRapeutics™ Serum from Myelofibrosis Donor, Serum, Myelofibrosis

Case Studies

Customer Reviews and Q&As

There are currently no customer reviews or questions for CellRapeutics™ Serum from Myelofibrosis Donor (XS-0426-XU138). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Immune Cell Products

T Cell Products

Dendritic Cell Products

Monocyte Products

B Cell Products

NK Cell Products

Control Cell Products

PBMC Products

Mouse Cell Products

Online Inquiry
Products
Global Services. (Creative Biolabs Authorized)
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

Key Updates
Newsletter. (Creative Biolabs Authorized) NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution. (Creative Biolabs Authorized) NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
Novel Solution. (Creative Biolabs Authorized) NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
New Technology. (Creative Biolabs Authorized) NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.
Copyright © 2026 Creative Biolabs. All Rights Reserved
  • 0
  • 0
Cart
    Go to checkout